Investor Presentation First Nine Months of 2022
55
Investor presentation First nine months of 2022
Novo NordiskⓇ
ONWARDS 4 achieved primary endpoint of HbA 1c non-inferiority
with no statistically significant difference in hypoglycaemic events
Change in HbA1c from baseline over time 26 weeks
Time since randomisation (weeks)
Overall hypoglycaemic episodes in the trial
Change from baseline (%)
0.0
-0.4
-0.8
-1.2
10
HH
18
КН
26 26*
On treatment
Insulin icodec
Insulin glargine U100
N
(%) E
R
N
(%) E R
Level 2:
Clinically
148
(50.9) 937
5.60
160 (55.0)
935
5.61
significant
hypo
Level 3:
4
(1.4)
7
0.04
(0.7)
3
0.018
-1.16%
Severe hypo
Level 3 or 2:
-1.18%
Severe or
clinically
150
(51.5)
944
5.64
162
(55.7)
938
5.62
significant
hypo
-1.6
Once-weekly insulin icodec Once-daily insulin glargine U100
Note: Overall baseline HbA1c of 8.3%
* Lines are based on observed data where the value denoted after 26 weeks is estimated mean value derived based on multiple imputation
Hypo: hypoglycaemia; N: Number of subjects with one or more events, %: Percentage of subjects with one or more events; E: Number of events; R: Rate (number of events per patient year of exposure, hypoglycaemia alert value (level 1): Plasma glucose value of
<3.9 mmol/L (70 mg/dL) and >= 3.0 mmol/L (54 mg/dL) confirmed by BG meter. Clinically significant hypoglycaemia (level 2): Plasma glucose value of < 3.0 mmol/L (54 mg/dL) confirmed by blood glycose meter. Severe hypoglycaemia (level 3): Hypoglycaemia with
severe cognitive impairment requiring external assistance for recovery.View entire presentation